# Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

> **NCT05717140** · PHASE1 · WITHDRAWN · sponsor: **Mayo Clinic**

## Conditions studied

- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Metastatic Malignant Neoplasm in the Lung
- Metastatic Melanoma
- Recurrent Melanoma
- Unresectable Melanoma

## Interventions

- **BIOLOGICAL:** Aerosol Sargramostim
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **OTHER:** Medical Device Usage and Evaluation
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT05717140
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-10-28
- **Primary completion:** 2026-01-28
- **Final completion:** 2026-01-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05717140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05717140, "Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05717140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*